Skoltech is a young organization and, thus, cannot offer many technologies for commercialization at the moment. However, many research projects are already ongoing or planned to be launched, so if your company is potentially interested in research cooperation with Skoltech, you are welcome to contact the Office of Grants and Contracts to discuss any research cooperation and sponsorship.
According to Skoltech IP policy, sponsors of research get additional preferences and benefits, such as a time-limited pre-emptive right to elect either a commercial royalty-free nonexclusive license or to negotiate a royalty-bearing exclusive license on the intellectual property created during the sponsored research.
Skoltech Case No. 2014-08-018
STATUS: LICENSED EXCLUSIVELY IN A FIELD OF USE
Inventors/Authors: Daniil Kononenko, Dr. Victor Lempitsky
The problem of gaze in videoconferencing has been attracting researchers and engineers for a long time. The problem manifests itself as the inability of the people engaged into a videoconferencing (the proverbial “Alice” and “Bob”) to maintain gaze contact. The lack of gaze contact is due to the disparity between Bob’s camera and the image of Alice’s face on Bob’s screen (and vice versa).
We revisit the problem of gaze correction and present a solution based on supervised machine learning. Unlike many previous solutions to gaze problem in videoconferencing, ours is purely monocular, i.e. it does not require any hardware apart from an in-built web-camera of a laptop. Being based on efficient machine learning predictors such as decision forests, the system is fast (runs in real-time on a single core of a modern laptop). More information >>>
Skoltech Case No. 2015-04-016,
Inventors/Authors: Prof. Vladimir Belyaev, Prof. Alexander Bolozdynya, Dr. Vadim Kantserov, Dr. Valery Sosnovtsev, Anastasia Berdnikova
According to the World Health Organization more than 7,5 million people die from cancer every year. In Russia at the beginning of 2011 more than 2,6 million patients were registered in oncological hospitals. Over the last 10 years the number of cancer patients in the country increased by 25.5%. Over the past 10 years, the number of cancer patients in the country increased by 25.5%. Most often, the probability of recovery from cancer is higher if pathological changes were diagnosed earlier. This requires highly accurate, efficient diagnostic tools, which are easy to use and safe for the patient. “Gamma-locator” is a device that meets all the listed requirements. More information >>>
Skoltech Case No. 2015-05-017
Inventors/Authors: Dr. Dmitry Kirsanov, Dr. Vitaly Panchuk, Dr. Maria Khaidukova, Dr. Andrey Legin
Calibration process for an analytical instrument may be long and tedious and may require the measurements with numerous standard samples which can be pretty expensive. Calibration model obtained for one instrument normally cannot be used directly with another, this leads to necessity of calibration for each particular instrument in use resulting in high costs for the maintenance. We suggest a procedure to avoid the calibration of the second instrument with the whole set of standard samples and measure only small subset of standards instead. After that based on the results of measurements with two instruments in the same small number of standard samples a mathematical transformation is performed to adjust the signal of the second instrument into the format of the first one. This allows for using the whole calibration model of the first instrument with the data from the second instrument. Unlike other calibration transfer protocols suggested so far the present one can deal with the signals from different analytical instruments having different nature of analytical signal, different number of variables in the signal. For example calibration model from X-ray fluorescence spectrometer can be transferred to UV-Vis spectrometer. More information >>>
If you are interested in any of the technologies from the list above please contact the KTO staff to discuss licensing opportunities or R&D collaboration.